drugset / Trial / NCT00745186

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers

NCT00745186

Phase 1 Completed 28 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.

Timeline

Start
2007-08
Primary completion
2007-10
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glucagon Peptide 0.2 mg Intramuscular
Comparator Glucagon Peptide 1 mg Intramuscular
Subject Mayne Glucagon Unknown 0.2 mg Intramuscular
Subject Mayne Glucagon Unknown 1 mg Intramuscular

Indications